NCT02502266 2026-03-05
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
Clinical Trials
6 trialsNCT04862585 2025-08-20
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
Ohio State University Comprehensive Cancer Center
Phase 2/3 Completed
NCT04499924 2025-01-22
MOUNTAINEER-02
Seagen Inc.
Phase 2/3 Completed
NCT01572727 2017-03-09
BELLE-4
Novartis
Phase 2/3 Completed
NCT01196741 2015-05-05
SaPPrOC
University College, London
Phase 2/3 Completed
NCT00507429 2014-06-09
FACT
Mateon Therapeutics
Phase 2/3 Terminated